Get access

Vemurafenib-Induced Neutrophilic Panniculitis in a Child with a Brainstem Glioma

Authors

  • Emily S. West B.S.,

    Corresponding author
    1. Columbia University College of Physicians and Surgeons, New York, New York
    • Address correspondence to Emily S. West, B.S., 630 West 168th Street, Room 1-420, Box 488, New York, NY 10032, or e-mail: ew2383@columbia.edu.

    Search for more papers by this author
  • Victoria L. Williams M.D.,

    1. Department of Dermatology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado
    2. Department of Pediatric Dermatology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado
    Search for more papers by this author
  • Joseph G. Morelli M.D.

    1. Department of Dermatology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado
    2. Department of Pediatric Dermatology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado
    3. Department of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado
    Search for more papers by this author

Abstract

Neutrophilic panniculitis is a rare adverse effect of therapy with selective BRAF inhibitors. We report a case of neutrophilic panniculitis in a 15-year-old girl receiving treatment with vemurafenib for a brainstem glioma. Clinicians should be aware of this rare but important side effect of vemurafenib. This is the first report of neutrophilic panniculitis in a child treated with vemurafenib.

Ancillary